Literature DB >> 12365855

Statins and renal function.

Moses Elisaf1, Dimitri P Mikhailidis.   

Abstract

Renal disease is often associated with an increased risk of vascular events. Moreover, an accelerated form of atherosclerosis commonly occurs in these patients. The reasons for these associations are not clearly defined but include the widespread presence of several established risk factors (eg, dyslipidemia, hypertension, and diabetes). Other predictors of atherosclerotic disease may also be abnormally elevated (eg, homocysteine, fibrinogen, and lipoprotein a). In addition, there is evidence that impaired renal function per se predicts vascular risk. Despite this high-risk background, the potential benefit of treatment with statins has not been widely investigated in these patients. The present review considers the evidence (experimental and clinical) that statins exert beneficial effects in patients with different types of renal disease. This includes improved renal function, decreased microalbuminuria, and a fall in blood pressure. Statins may also improve renal allograft survival. The potential mechanisms mediating these effects are considered. The interactions between statins and several risk factors that may be present in patients with impaired renal function are also considered. There is an urgent need to define the role of statins in these high-risk patients. Which is the statin of choice? This question is relevant because impaired renal function can interfere with statin pharmacokinetics. Furthermore, other drugs administered to these patients may cause serious interactions with statins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12365855     DOI: 10.1177/000331970205300501

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  9 in total

Review 1.  Lipid abnormalities in kidney disease and management strategies.

Authors:  Vishwam Pandya; Akhilesh Rao; Kunal Chaudhary
Journal:  World J Nephrol       Date:  2015-02-06

Review 2.  Risks and benefits of statin use in young people with type 1 diabetes.

Authors:  Petter Bjornstad; R Paul Wadwa
Journal:  Curr Diab Rep       Date:  2014-07       Impact factor: 4.810

Review 3.  Treatment of lipids and type 2 diabetes.

Authors:  Kathie L Hermayer
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

4.  The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

Authors:  V G Athyros; D P Mikhailidis; A A Papageorgiou; A N Symeonidis; A N Pehlivanidis; V I Bouloukos; M Elisaf
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

Review 5.  Should a statin be prescribed to every patient with heart failure?

Authors:  Sofia G Tsouli; Evangelos N Liberopoulos; John A Goudevenos; Dimitri P Mikhailidis; Moses S Elisaf
Journal:  Heart Fail Rev       Date:  2007-08-12       Impact factor: 4.214

Review 6.  Statins in heart failure: do we need another trial?

Authors:  Kwadwo Osei Bonsu; Amudha Kadirvelu; Daniel Diamond Reidpath
Journal:  Vasc Health Risk Manag       Date:  2013-06-17

7.  The Association Between Statin Use and Risk of Chronic Kidney Disease in Community-Dwelling Older People in Shanghai, China.

Authors:  Miaomiao Zhao; Longbing Ren; Zhitong Zhou; Tao Wang; Jue Li
Journal:  Clin Epidemiol       Date:  2022-06-25       Impact factor: 5.814

Review 8.  Circulatory syndrome: an evolution of the metabolic syndrome concept!

Authors:  Ali Reza Khoshdel; Shane L Carney; Alastair Gillies
Journal:  Curr Cardiol Rev       Date:  2012-02

9.  Clinical profile of long-term survivors and nonsurvivors with type 2 diabetes.

Authors:  Viswanathan Mohan; Coimbatore Subramanian Shanthi Rani; Anandakumar Amutha; Sravan Dhulipala; Ranjit Mohan Anjana; Balasubramanian Parathasarathy; Ranjit Unnikrishnan
Journal:  Diabetes Care       Date:  2013-04-05       Impact factor: 19.112

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.